See the DrugPatentWatch profile for Tresiba
When does Tresiba's main patent expire?
The primary patent protecting Tresiba (insulin degludec) is set to expire in November 2027 [1]. This patent covers the active pharmaceutical ingredient.
What happens after Tresiba's patent expires?
Following patent expiry, the market could open for generic or biosimilar versions of Tresiba. This typically leads to increased competition and potentially lower prices for the medication. DrugPatentWatch.com tracks patent expirations and market exclusivities for many drugs, including Tresiba [1].
Are there other exclusivity periods for Tresiba?
In addition to patent protection, regulatory exclusivities can extend market protection. For example, in the United States, Tresiba received 12 years of data exclusivity, which began when it was approved by the FDA. This exclusivity period would have ended in early 2027. However, the patent expiry in November 2027 still provides a key barrier to generic entry [1].
Who manufactures Tresiba?
Tresiba is manufactured by Novo Nordisk [2].
How does Tresiba work for diabetes management?
Tresiba is a long-acting basal insulin used to improve glycemic control in adults, adolescents, and children aged 1 year and older with diabetes mellitus [2]. It works by regulating glucose metabolism.
What are the differences between Tresiba and other insulins?
Tresiba is an ultra-long-acting basal insulin with a duration of action exceeding 42 hours. This allows for more dosing flexibility compared to other basal insulins, which typically have a duration of around 24 hours [2]. The specific amino acid sequence and formulation contribute to its prolonged action.
What are the potential risks associated with Tresiba?
The most common side effect of Tresiba, like other insulins, is hypoglycemia (low blood sugar) [2]. Other potential risks include injection site reactions and allergic reactions.
What is the clinical data supporting Tresiba's use?
Clinical trials have demonstrated Tresiba's efficacy in reducing blood glucose levels and its safety profile in various patient populations with type 1 and type 2 diabetes [2].
How is Tresiba administered?
Tresiba is administered via subcutaneous injection [2].
---
Sources:
1. https://drugpatentwatch.com/
2. Novo Nordisk